The American Society of Hematology (ASH), the world’s largest professional association of hematologists concerned with the causes and treatment of blood disorders, expects more than 20,000 attendees at the 50th ASH Annual Meeting from December 6-9, 2008, at the Moscone Center in San Francisco, CA. The meeting will showcase the latest research and treatments for blood disorders. In honor of the Society’s golden anniversary,…Continue
Added by Peter Hofland, PhD on December 5, 2008 at 8:00pm — No Comments
Added by Peter Hofland, PhD on December 5, 2008 at 5:30pm — No Comments
Added by Peter Hofland, PhD on December 5, 2008 at 5:00pm — No Comments
How common is the tumorigenic potential or tumor promoting property in human cancers? For many years, cancer researchers have tried to answer the fundamental question whether all tumor cells are equally likely to cause new cancers.
A generally supported idea is that only a tiny subset of highly prolific cancer cells, dubbed cancer stem cells and…
Added by Peter Hofland, PhD on December 5, 2008 at 12:30pm — No Comments
Positron emission mammography or PEM, a new technique for imaging the breast, is not affected by either breast density or a woman’s hormonal status, two factors that limit the effectiveness of standard mammography and MRI at detecting cancer, according to a study presented during the 94th Scientific Assembly and Annual Meeting (November 30 – December 5, 2008) of the…Continue
Added by Peter Hofland, PhD on December 5, 2008 at 8:00am — No Comments
Added by Peter Hofland, PhD on December 4, 2008 at 10:00pm — No Comments
Stem cells derived from bone marrow may serve as a novel therapeutic option to treat a disease called epidermolysis bullosa (EB), a disorder characterized by extraordinarily fragile skin, according to a study pre-published online in Blood, the official journal of the American Society of Hematology.
Epidermolysis bullosa is a…
Added by Peter Hofland, PhD on December 4, 2008 at 5:00pm — No Comments
New research reveals that computed tomography (CT) colonography, also known as virtual colonoscopy, has the potential to screen for two diseases at once—colorectal cancer and osteoporosis, both of which commonly affect adults over age 50. The results of this study were presented on Tuesday at the 94th Scientific Assembly and Annual Meeting (November 30 – December 5, 2008) of the Radiological Society of North America…Continue
Added by Peter Hofland, PhD on December 4, 2008 at 4:00pm — No Comments
Women with early-stage breast cancer who have undergone breast augmentation may be treated successfully with a partial-breast radiation treatment called brachytherapy, according to a study presented at the 94th Scientific Assembly and Annual Meeting (November 30 – December 5, 2008) of the Radiological Society of North America (RSNA) on Monday. Patients treated with brachytherapy have better cosmetic outcomes and avoid the risk of…Continue
Added by Peter Hofland, PhD on December 4, 2008 at 3:30pm — No Comments
Prostate cancer is among the most prevalent cancers in the developed world. It also remains one of the most complex diseases to treat. According to the American Cancer Society prostate cancer is a leading cause of cancer-related deaths. While the advent of PSA (prostate specific antigen) testing has shifted detection from late-stage disease to early-stage disease, it has also raised the challenge of distinguishing between fast-growing cancers that must be treated aggressively versus…Continue
Added by Peter Hofland, PhD on April 12, 2007 at 1:00pm — No Comments
Added by Peter Hofland, PhD on November 28, 2005 at 8:00pm — No Comments
Added by Peter Hofland, PhD on September 18, 2005 at 1:30pm — No Comments
Policymakers often raise the question “Do ‘new’ and innovative drugs costs too much?”. Although innovative ‘new’ drugs may be more expensive than alternative, existing, drug therapies, they are extensively reviewed for their benefits and costs and are considered to be among the most cost effective treatments available. Furthermore, ‘new’ drugs are also expected to reduce mortality in diseases that claim many lives today, such as cancer.
So, are ‘new’ and innovative…
Added by Peter Hofland, PhD on September 12, 2004 at 8:00pm — No Comments
Temoporfin-mediated photodynamic therapy represents a major advance in the treatment of head and neck cancer, yielding complete response rates comparable with those published for surgery or radiotherapy, according to phase II data reported here last week during ECCO 11, the European Cancer Conference.
Temoporfin-mediated photodynamic therapy (Foscan PDT) is an "effective and well-tolerated treatment" and can be administered without surgery, said Dr. Colin Hopper, a consultant…Continue
Added by Peter Hofland, PhD on November 1, 2001 at 4:00pm — No Comments